Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alzamend Neuro Inc
(NQ:
ALZN
)
0.6336
-0.0154 (-2.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alzamend Neuro Inc
< Previous
1
2
Next >
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
May 17, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Pricing of Initial Public Offering
June 14, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
May 05, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
April 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
April 28, 2022
From
BitNile Holdings, Inc.
Via
Business Wire
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
April 11, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
April 04, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
March 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
December 17, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics
December 15, 2021
Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also...
Via
FinancialNewsMedia
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
November 30, 2021
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
September 30, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
September 13, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
August 17, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
August 04, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
July 30, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
July 28, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
July 23, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
July 12, 2021
From
Alzamend Neuro
Via
Business Wire
Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease
July 01, 2021
From
Ault Global Holdings, Inc.
Via
Business Wire
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
July 01, 2021
From
Alzamend Neuro
Via
Business Wire
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
June 17, 2021
From
Alzamend Neuro, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.